Ratiopharm

Executive Summary

Ratiopharm GmbH, a subsidiary of Teva Pharmaceutical Industries, is Germany's leading generic drug manufacturer and the country's best-known pharmaceutical brand. Headquartered in Ulm and founded in 1973, the company offers a broad portfolio of approximately 2,500 products spanning prescription generics, over-the-counter medicines, and consumer health. Leveraging Teva's global R&D infrastructure and scale, Ratiopharm maintains a strong market position in the German generics market, where it competes on cost, reliability, and brand trust. The company's extensive product lineup and deep pharmacy relationships provide a resilient revenue base, underpinned by the steady demand for affordable medications in Europe's largest healthcare market. As a private entity, Ratiopharm benefits from the financial stability and operational synergies of its parent company. While the generics segment faces pricing pressures and competition, Ratiopharm's established brand and wide coverage mitigate downside risk. The company is well-positioned to capitalize on upcoming patent expiries of several blockbuster drugs, expand its consumer health offerings, and explore biosimilar opportunities. Continued focus on efficiency and expansion into near-patient and specialty segments could sustain growth. Overall, Ratiopharm represents a stable, core generics play with moderate growth prospects driven by a steady stream of new product launches and regulatory approvals.

Upcoming Catalysts (preview)

• Q4 2026Launch of generic version of key cardiovascular drug (e.g., apixaban)85% success
• Q2 2027Expansion of consumer health portfolio via new OTC approvals70% success
• H2 2027Strategic partnership for biosimilar development in Europe50% success